At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 116 enrolled
Drug / intervention
S-equol +1 moredrug
Likely dose
S-equol 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS 131 (S Equol) on Benign Prostatic Hyperplasia
In Brief
A Phase 2 clinical trial evaluating S-equol and Placebo for Benign Prostatic Hyperplasia. Completed, enrolled 116 participants across 15 sites in 2 countries.
Detailed Summary
The purpose of this study is to assess the safety and effectiveness of S-equol in men with benign prostatic hyperplasia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBenign Prostatic Hyperplasia
CountriesIndia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2009
First PostedAug 2009
Primary CompletionJan 2016
TodayJul 2026
First PostedAug 20, 2009
Enrollment StartJun 1, 2009
Primary CompletionJan 1, 2016
TodayJul 2, 2026
Enrollment to primary: 6.6 yearsPosted 16.9 years ago
Interventions
S-equoldrug
10mg S-equol 50mg S-equol, \& 150mg S-equol
Placebodrug
Placebo